Homology Medicines (FIXX) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FIXX shares.
View FIXX analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1 year target prices for Homology Medicines' stock. Their FIXX share price forecasts range from $2.10 to $20.00. On average, they predict the company's stock price to reach $8.73 in the next year. This suggests a possible upside of 786.1% from the stock's current price.
View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts.

Homology Medicines' stock was trading at $1.26 on January 1st, 2023. Since then, FIXX shares have decreased by 21.8% and is now trading at $0.9850.
View the best growth stocks for 2023 here.

Homology Medicines saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 268,800 shares, a decline of 23.4% from the April 30th total of 351,000 shares. Based on an average daily volume of 154,100 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.6% of the shares of the stock are sold short.
View Homology Medicines' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our FIXX earnings forecast.

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Thursday, March, 9th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.09. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.05 million. Homology Medicines had a negative trailing twelve-month return on equity of 64.66% and a negative net margin of 3,926.25%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.08%), Bank of America Corp DE (0.73%), Renaissance Technologies LLC (0.54%), Connor Clark & Lunn Investment Management Ltd. (0.30%), Dimensional Fund Advisors LP (0.23%) and FMR LLC (0.13%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, Kush Parmar, Michael Lee Blum, Paul Alloway, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends.

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FIXX stock can currently be purchased for approximately $0.99.

Homology Medicines (NASDAQ:FIXX) has a market capitalization of $56.92 million and generates $3.21 million in revenue each year. The company earns $-5,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

The company employs 224 workers across the globe.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The official website for the company is www.homologymedicines.com. The company can be reached via phone at (781) 301-7277.